Relaxin and breast cancer

Area of Science:

• Endocrinology
• Molecular Biology
• Cancer Research

Background:

• Relaxin is a peptide hormone with diverse biological activities.
• The mammary gland is a key target for relaxin, influencing tissue growth and differentiation.
• Relaxin's impact on breast cancer cells warrants investigation.

Purpose of the Study:

• To investigate the effects of relaxin on MCF-7 breast adenocarcinoma cells in vitro.
• To explore relaxin's influence on cancer cell proliferation, differentiation, and adhesion.
• To elucidate the mechanisms underlying relaxin's action on breast cancer cells.

Main Methods:

• In vitro culture of MCF-7 breast adenocarcinoma cells.
• Treatment with varying concentrations of relaxin over short and long exposure times.
• Co-culture with myoepithelial cells to mimic in vivo microenvironment.
• Analysis of cell proliferation, differentiation markers, adhesion molecules, and nitric oxide synthesis.

Main Results:

• Relaxin exhibited a biphasic effect on MCF-7 cell proliferation: stimulation at nanomolar and inhibition at micromolar concentrations.
• Long-term exposure to relaxin inhibited cell growth and promoted differentiation and adhesion molecule expression.
• Co-culturing with myoepithelial cells enhanced relaxin's differentiation-promoting effects.
• Relaxin's inhibitory and differentiation effects appear mediated by nitric oxide synthesis activation.

Conclusions:

• Relaxin demonstrates significant anti-cancer properties against MCF-7 cells, including growth inhibition and differentiation induction.
• The microenvironment, including myoepithelial cells, can modulate relaxin's effects.
• Nitric oxide signaling is a likely pathway for relaxin's anti-cancer actions.